Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumes:
Volumen 37, 2020 Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v23.i5.20
pages 401-436

Antibodies and Peptides in Cancer Therapy

Jayant J. Khandare
Department of Pharmaceutics, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
Tamara Minko
Associate Professor, Dept. of Pharmaceutics, School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020

SINOPSIS

Antibodies and peptides play a variety of roles in cancer therapy: monoclonal antibodies (mAbs) and peptides are directly used in anticancer therapy and also as targeting moieties. More than 10 mAbs, either unconjugated or in immunoconjugate forms have been approved for use in oncology. Various peptides, tumor necrosis factors (TNFs), and cell surface-targeted peptides have been identified using phage-display libraries. In combination with standard chemotherapeutic agents, mAbs and peptides can significantly increase the toxicity of anticancer drugs to tumors and reduce their adverse side effects on normal tissues. The present review summarizes some major applications of antibodies and peptides in cancer therapy.